Saint-Priez en Jarez, France Clinical Trials

A listing of Saint-Priez en Jarez, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 12 clinical trials
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).

Institut de Canc rologie de Loire
 (0.0 away) Contact site
  • 23 Nov, 2020
  • +348 other locations
Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence

Stereo-Re-Pro aims to provide further evidence of Stereotactic Body Radiotherapy (SBRT) as a supplementary non-invasive curative treatment for local recurrence following radiotherapy. The objective of the first part of the trial (Phase I) is to select the recommended dose for salvage SBRT (either 5 x 6 Gy, 6 x 6 …

Institut de Canc rologie Lucien Neuwirth
 (0.5 away) Contact site
  • 30 Sep, 2020
  • +14 other locations
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients

INDICATION: Oligometastatic hormone-sensitive prostate cancer patients. METHODOLOGY: Open label, double arm, randomized 1:1, multicenter phase III study. PRIMARY OBJECTIVE: To assess the efficacy of ablative radiotherapy (SBRT applied to all oligometastases) administered to all gross tumor sites (metastases and prostate if applicable), in oligometastatic hormone-sensitive prostate cancer patients.

CHU Lyon Sud
 (26.5 away) Contact site
  • 20 Sep, 2020
  • +20 other locations
Haemophilia and Bone Loss - PHILEOS Study

Haemophilia is a rare bleeding disorder, characterized by factor VIII (HA) or factor IX (HB) deficiency. The absence or the reduction of fVIII or fIX result in impaired thrombin generation and clot formation, causing excessive bleeding (mainly haemarthrosis). Osteoporosis is a systemic bone disease characterized by a low bone mineral …

christmas disease
antihemophilic factor
severe haemophilia a
CHU de Saint-Etienne
 (2.4 away) Contact site
  • 22 Oct, 2020
  • +14 other locations
Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients

Metastatic prostate cancer has traditionally been regarded as an incurable dissemination of disease, and treatment is focused on delaying progression rather than eliminating all tumor burden. Local therapies, and specifically radiotherapy, have been directed at quality of life endpoints and not at improving survival. However, advances in imaging and systemic …

metastatic prostate cancer
prostate cancer metastatic
serum testosterone
adenocarcinoma of prostate
Centre L on B rard
 (29.7 away) Contact site
  • 23 Feb, 2020
  • +17 other locations
Physical Activity Experiment on Male Prostate Cancer Patients

Prostate cancer is the most common cancer in France (56,841 cases in 2012). Although the benefits of physical activity (PA) in cancer patients are currently well established in the scientific literature, several studies have shown that this population is not sufficiently active. Strengthen patient adherence to prevention counseling by the …

CHU Saint-Etienne
 (2.4 away) Contact site
  • 14 Oct, 2020
  • +4 other locations
Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)

As in other solid tumours, increasing evidence indicates that patients diagnosed with a limited number of prostate cancer metastases, so-called oligometastases, have a better prognosis compared with patients with extensive metastatic disease. Survival of patients with three or fewer metastases was superior compared with patients with more than three lesions. …

neutrophil count
platelet count
stereotactic body radiation therapy
Hospices Civils de Lyon
 (26.6 away) Contact site
  • 20 May, 2019
  • +8 other locations
Mindfulness and Cognition in Schizophrenia

Mindfulness (innovative and integrative practice in care) allows the individual to adapt his/her behavior (physical and emotional), in a stressful environment, by regulating cardiac activity, especially the parasympathetic system. In schizophrenia, despite the positive effect of treatments on symptoms (delusions and hallucinations), patients have altered markers of the parasympathetic (high …

CHU Saint Etienne
 (2.4 away) Contact site
  • 13 Apr, 2020
  • +1 other locations
Combined Apalutamide Radiotherapy and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

This is a multicenter, randomized, open label, phase III study comparing the efficacy and safety of apatulamide combined with concomitant prostate-bed salvage radiotherapy (SRT) and androgen deprivation therapy (ADT) versus concomitant prostate-bed SRT and ADT in high-risk postprostatectomy biochemically relapsed prostate cancer patients.

adenocarcinoma of prostate
luteinizing hormone-releasing hormone agonist
Centre Hospitalier Emile ROUX
 (38.2 away) Contact site
  • 01 Oct, 2020
  • +21 other locations
Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy

The TEMPOS-GEniToUrinary Group (GETUG) study is a multicenter, randomized-controlled medico-economic study comparing brachytherapy to SBRT in low and intermediate risk prostate cancer, particularly focused on the issue of erectile dysfunction. A total of 240 potent patients are randomized in two arms. The experimental arm consists of SBRT delivering 7.25 Gy …

adenocarcinoma of prostate
H pital Lyon Sud
 (26.5 away) Contact site
  • 03 Feb, 2020
  • +15 other locations